Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15040) 15040
Book Review (2330) 2330
Publication (1467) 1467
Book Chapter (151) 151
Conference Proceeding (38) 38
Dissertation (16) 16
Magazine Article (11) 11
Newsletter (8) 8
Book / eBook (6) 6
Paper (2) 2
Reference (2) 2
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (13186) 13186
animals (7585) 7585
humans (7321) 7321
male (6006) 6006
phosphodiesterase inhibitors - pharmacology (3624) 3624
rats (2959) 2959
pharmacology & pharmacy (2553) 2553
phosphodiesterase (2390) 2390
female (2273) 2273
mice (2124) 2124
sildenafil citrate (1957) 1957
sildenafil (1855) 1855
biochemistry & molecular biology (1830) 1830
erectile dysfunction (1774) 1774
phosphodiesterase inhibitors - therapeutic use (1737) 1737
middle aged (1672) 1672
cyclic amp - metabolism (1580) 1580
urology & nephrology (1418) 1418
erectile dysfunction - drug therapy (1413) 1413
adult (1358) 1358
cell biology (1342) 1342
dose-response relationship, drug (1320) 1320
neurosciences (1301) 1301
analysis (1185) 1185
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (1182) 1182
cells, cultured (1159) 1159
aged (1154) 1154
expression (1072) 1072
camp (1068) 1068
tadalafil (998) 998
treatment outcome (974) 974
rats, sprague-dawley (965) 965
signal transduction (965) 965
in vitro techniques (959) 959
impotence (958) 958
nitric oxide (956) 956
cyclic gmp - metabolism (955) 955
3',5'-cyclic-amp phosphodiesterases - metabolism (954) 954
phosphodiesterase inhibitors (954) 954
phosphoric diester hydrolases - metabolism (937) 937
research (925) 925
phosphorylation (924) 924
physiology (924) 924
nitric-oxide (898) 898
cyclic nucleotide phosphodiesterases, type 4 (876) 876
piperazines - therapeutic use (875) 875
abridged index medicus (870) 870
activation (861) 861
proteins (841) 841
enzyme inhibitors - pharmacology (831) 831
purines (825) 825
cells (814) 814
piperazines - pharmacology (812) 812
phosphodiesterase 5 inhibitors - therapeutic use (810) 810
article (790) 790
rolipram (784) 784
enzymes (777) 777
sulfones (777) 777
phosphodiesterases (775) 775
disease models, animal (773) 773
rats, wistar (747) 747
cardiac & cardiovascular systems (734) 734
time factors (728) 728
physiological aspects (718) 718
inhibition (700) 700
inhibitors (696) 696
apoptosis (691) 691
kinetics (682) 682
cyclic nucleotide phosphodiesterases, type 5 (680) 680
cgmp (655) 655
care and treatment (652) 652
rodents (649) 649
in-vitro (637) 637
cyclic amp (636) 636
double-blind (630) 630
cyclic-nucleotide phosphodiesterases (625) 625
health aspects (620) 620
inflammation (617) 617
drug therapy (607) 607
chemistry, medicinal (605) 605
phosphodiesterase inhibitors - administration & dosage (593) 593
calcium - metabolism (592) 592
signal transduction - drug effects (587) 587
men (583) 583
cell line (580) 580
gene expression (572) 572
1-methyl-3-isobutylxanthine - pharmacology (558) 558
mice, inbred c57bl (556) 556
multidisciplinary sciences (525) 525
hypertension (523) 523
nitric-oxide synthase (521) 521
medicine & public health (520) 520
research article (507) 507
respiratory system (505) 505
double-blind method (503) 503
risk factors (503) 503
3',5'-cyclic-gmp phosphodiesterases - antagonists & inhibitors (501) 501
medicine (501) 501
sphingomyelin phosphodiesterase - metabolism (497) 497
phosphodiesterase inhibitors - adverse effects (496) 496
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14812) 14812
German (72) 72
French (69) 69
Russian (50) 50
Chinese (37) 37
Japanese (34) 34
Spanish (25) 25
Korean (10) 10
Portuguese (10) 10
Italian (4) 4
Polish (4) 4
Dutch (3) 3
Turkish (3) 3
Bulgarian (2) 2
Czech (2) 2
Swedish (2) 2
Croatian (1) 1
Danish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Slovak (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma
by Loeb, Stacy and Folkvaljon, Yasin and Lambe, Mats and Robinson, David and Garmo, Hans and Ingvar, Christian and Stattin, Pär
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 06/2015, Volume 313, Issue 24, pp. 2449 - 2455
IMPORTANCE The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicated in the development... 
UNITED-STATES | SWEDEN | SURVIVAL | DIAGNOSIS | REGISTER | MEDICINE, GENERAL & INTERNAL | INCIDENT MELANOMA | SILDENAFIL | PROSTATE-CANCER | MEN | COHORT | Phosphodiesterase 5 Inhibitors - adverse effects | Carcinoma, Basal Cell - chemically induced | Humans | Middle Aged | Risk Factors | Logistic Models | Male | Skin Neoplasms - chemically induced | Case-Control Studies | Socioeconomic Factors | Drug Prescriptions - statistics & numerical data | Sweden | Animals | Erectile Dysfunction - drug therapy | Melanoma - chemically induced | Aged, 80 and over | Registries | Aged | Phosphodiesterase 5 Inhibitors - therapeutic use | Care and treatment | Dosage and administration | Phosphodiesterases | Impotence | Risk factors | Melanoma | Inhibitor drugs | Risk assessment | Clinical outcomes | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer
by Lian, Yi|Yin, Hui|Pollak, Michael N.|Carrier, Serge|Platt, Robert W.|Suissa, Samy|Azoulay, Laurent
European Urology, ISSN 0302-2838, 2016, Volume 70, Issue 5, pp. 808 - 815
Abstract Background The association between phosphodiesterase type 5 inhibitors (PDE5-Is), drugs used in the treatment of erectile dysfunction (ED), and... 
Urology | Squamous cell carcinoma | Erectile dysfunction | Basal cell carcinoma | Phosphodiesterase type 5 inhibitors | Melanoma skin cancer | METAANALYSIS | EFFICACY | TADALAFIL | PRACTICE RESEARCH DATABASE | CELL CARCINOMA | 5 inhibitors | Phosphodiesterase type | PATHWAY | CUTANEOUS MELANOMA | MEN | UROLOGY & NEPHROLOGY | HUMAN HOMOLOG | Melanoma - epidemiology | Skin Neoplasms - pathology | Risk Assessment - methods | Carcinoma, Squamous Cell - epidemiology | Phosphodiesterase 5 Inhibitors - adverse effects | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Proportional Hazards Models | Erectile Dysfunction - diagnosis | Male | Medication Therapy Management | Carcinoma, Basal Cell - epidemiology | Carcinoma, Basal Cell - pathology | Melanoma - pathology | Skin Neoplasms - epidemiology | Drug Prescriptions - statistics & numerical data | Erectile Dysfunction - drug therapy | Aged | United Kingdom - epidemiology | Impotence | Health aspects | Epidemiology | Risk factors | Melanoma | Skin cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models
by Ilg, Marcus M and Mateus, Marta and Stebbeds, William J and Milenkovic, Uros and Christopher, Nim and Muneer, Asif and Albersen, Maarten and Ralph, David J and Cellek, Selim
European Urology, ISSN 0302-2838, 02/2019, Volume 75, Issue 2, pp. 329 - 340
Peyronie's disease (PD) is a fibrotic disorder of the penile tunica albuginea, characterised by the formation of a localised fibrous plaque that can lead to... 
Phenotypic screening | Peyronie's disease | Myofibroblast | Fibrosis | Phosphodiesterase type 5 inhibitor | Oestrogen receptor modulator | Fibroblast | Fibroproliferative | Tunica albuginea | COMBINATION THERAPY | TAMOXIFEN | RAT MODEL | FIBROBLASTS | GROWTH-FACTOR-BETA | Phosphodiesterase type | CONTRACTION | MEN | UROLOGY & NEPHROLOGY | MYOFIBROBLASTS | 5 inhibitor | SMAD | Penis - pathology | Penile Induration - pathology | Penis - enzymology | Penile Induration - drug therapy | Humans | Myofibroblasts - enzymology | Male | Penile Induration - enzymology | Penis - drug effects | Vardenafil Dihydrochloride - pharmacology | Drug Therapy, Combination | Phosphodiesterase 5 Inhibitors - pharmacology | Disease Models, Animal | Myofibroblasts - pathology | Extracellular Matrix - drug effects | Cells, Cultured | Myofibroblasts - drug effects | Rats, Sprague-Dawley | Drug Synergism | Extracellular Matrix - enzymology | Phenotype | Animals | High-Throughput Screening Assays | Tamoxifen - pharmacology | Extracellular Matrix - pathology | Selective Estrogen Receptor Modulators - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Acute Nonarteritic Anterior Ischemic Optic Neuropathy and Exposure to Phosphodiesterase Type 5 Inhibitors
by Campbell, Ulka B and Walker, Alexander M and Gaffney, Michael and Petronis, Kenneth R and Creanga, Dana and Quinn, Sheila and Klein, Barbara E.K and Laties, Alan M and Lewis, Michael and Sharlip, Ira D and Kolitsopoulos, Francesca and Klee, Brian J and Mo, Jingping and Reynolds, Robert F
The Journal of Sexual Medicine, ISSN 1743-6095, 01/2015, Volume 12, Issue 1, pp. 139 - 151
Nonarteritic anterior ischemic optic neuropathy (NAION), a rare visual disorder, has been reported in men using phosphodiesterase type 5 inhibitors (PDE5i) for... 
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) | Sildenafil | Phosphodiesterase Type 5 Inhibitors (PDE5i) | Case–Crossover Study | Erectile Dysfunction (ED) | Erectile Dysfunction | NAION | Nonarteritic Anterior Ischemic Optic Neuropathy | Case-Crossover Study | ERECTILE-DYSFUNCTION | SAFETY | UROLOGY & NEPHROLOGY | GENERAL-PRACTICE | CASE-CROSSOVER DESIGN | ENGLAND | United States - epidemiology | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Risk Factors | Logistic Models | Male | Erectile Dysfunction - epidemiology | Case-Control Studies | Optic Neuropathy, Ischemic - pathology | Erectile Dysfunction - drug therapy | Optic Neuropathy, Ischemic - chemically induced | Aged | Phosphodiesterase 5 Inhibitors - therapeutic use | Optic Neuropathy, Ischemic - epidemiology | Eye diseases | Ophthalmology | Impotence | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy
by Michl, Uwe|Molfenter, Frederike|Graefen, Markus|Tennstedt, Pierre|Ahyai, Sascha|Beyer, Burkhard|Budäus, Lars|Haese, Alexander|Heinzer, Hans|Oh, Su Jung|Salomon, Georg|Schlomm, Thorsten|Steuber, Thomas|Thederan, Imke|Huland, Hartwig|Tilki, Derya
Journal of Urology, The, ISSN 0022-5347, 2015, Volume 193, Issue 2, pp. 479 - 483
Purpose Experimental evidence suggests that phosphodiesterase type 5 inhibitors may suppress tumor growth, postpone metastasis and prolong survival, but... 
Urology | recurrence | prostatectomy | phosphodiesterase 5 inhibitors | prostatic neoplasms | ACTIVATION | CANCER | PRESERVATION | RECOVERY | CELL FUNCTION | MEN | EXISULIND | UROLOGY & NEPHROLOGY | RETROPUBIC PROSTATECTOMY | ANTITUMOR IMMUNITY | ERECTILE DYSFUNCTION | Follow-Up Studies | Prostatic Neoplasms - surgery | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Neoplasm Recurrence, Local - chemically induced | Male | Prostatectomy | Aged | Retrospective Studies | Prostatic Neoplasms - chemically induced | Prostate cancer | Usage | Surgery | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 Study): A randomized controlled trial
by Tapson, Victor F and Jing, Zhi-Cheng and Xu, Kai-Feng and Pan, Lei and Feldman, Jeremy and Kiely, David G and Kotlyar, Eugene and McSwain, C. Shane and Laliberte, Kevin and Arneson, Carl and Rubin, Lewis J and FREEDOM-C2 Study Team
Chest, ISSN 0012-3692, 2013, Volume 144, Issue 3, pp. 952 - 958
Background: Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) as parenteral or inhaled therapy.... 
INHALED ILOPROST | SILDENAFIL | EFFICACY | RESPIRATORY SYSTEM | DOUBLE-BLIND | SUBCUTANEOUS INFUSION | BOSENTAN | CRITICAL CARE MEDICINE | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Exercise Tolerance - drug effects | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Female | Blood Pressure - drug effects | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Phosphodiesterase 5 Inhibitors - administration & dosage | Familial Primary Pulmonary Hypertension | Treatment Outcome | Epoprostenol - analogs & derivatives | Adolescent | Aged | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Complications and side effects | Care and treatment | Patient outcomes | Treprostinil | Clinical trials | Dosage and administration | Research | Drug therapy | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis
by Tang, Huilin and Wu, Wenting and Fu, Shuangshuang and Zhai, Suodi and Song, Yiqing and Han, Jiali
Journal of the American Academy of Dermatology, ISSN 0190-9622, 09/2017, Volume 77, Issue 3, pp. 480 - 488.e9
The association between phosphodiesterase type 5 (PDE5) inhibitors and melanoma risk is controversial. We quantify the association between use of PDE5... 
meta-analysis | basal cell carcinoma | melanoma | PDE5 inhibitor | squamous cell carcinoma | SILDENAFIL | ERECTILE DYSFUNCTION | DERMATOLOGY | Melanoma - epidemiology | Melanoma - chemically induced | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Risk Factors | Observational Studies as Topic | Skin Neoplasms - chemically induced | Skin Neoplasms - epidemiology | Drugstores | Epidemiology | Pharmacy | Public health | Melanoma | Squamous cell carcinoma | Skin cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Phosphodiesterase type 5 (PDE5) inhibitors sensitize topoisomerase II inhibitors in killing prostate cancer through PDE5-independent impairment of HR and NHEJ DNA repair systems
by Chang, Jo-Fan and Hsu, Jui-Ling and Sheng, Yi-Hua and Leu, Wohn-Jenn and Yu, Chia-Chun and Chan, She-Hung and Chan, Mei-Ling and Hsu, Lih-Ching and Liu, Shih-Ping and Guh, Jih-Hwa
Frontiers in Oncology, ISSN 2234-943X, 2019, Volume 9, pp. 681 - 681
Human castration-resistant prostate cancer (CRPC) is a significant target of clinical research. The use of DNA-damaging agents has a long history in cancer... 
Phosphodiesterase type 5 inhibitor | Non-homologous end joining DNA repair | Topoisomerase II inhibitor | Homologous recombination DNA repair | PDE5-independent | PATHWAYS | CELLS | APOPTOSIS | phosphodiesterase type 5 inhibitor | SILDENAFIL | homologous recombination DNA repair | REPLICATION PROTEIN-A | DOXORUBICIN | DOWN-REGULATION | CHEMOTHERAPY | DAMAGE RESPONSE | ONCOLOGY | DRUGS | non-homologous end joining DNA repair | topoisomerase II inhibitor | Usage | Care and treatment | Research | Phosphodiesterases | DNA repair | Prostate cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?
by Feng, Shijian and Zhou, Liang and Liu, Qinyu and He, Qing and Liao, Banghua and Wei, Xin and Li, Hong and Wang, Kunjie and Zhu, Yuchun
Medicine (United States), ISSN 0025-7974, 01/2018, Volume 97, Issue 3
melanoma | phosphodiesterase type 5 inhibitor | systematic review | risk factor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial
by Tapson, Victor F and Torres, Fernando and Kermeen, Fiona and Keogh, Anne M and Allen, Roblee P and Frantz, Robert P and Badesch, David B and Frost, Adaani E and Shapiro, Shelley M and Laliberte, Kevin and Sigman, Jeffrey and Arneson, Carl and Galiè, Nazzareno
Chest, ISSN 0012-3692, 2012, Volume 142, Issue 6, pp. 1383 - 1390
Background: Infused and inhaled treprostinil are effective for treatment of pulmonary arterial hypertension (PAH), although their administration routes have... 
INHALED ILOPROST | TRANSITION | MULTICENTER | SILDENAFIL | RESPIRATORY SYSTEM | INTRAVENOUS EPOPROSTENOL | PROSTACYCLIN | DOUBLE-BLIND | INFECTION | SUBCUTANEOUS INFUSION | BOSENTAN THERAPY | CRITICAL CARE MEDICINE | Sulfones - therapeutic use | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Walking - physiology | Dose-Response Relationship, Drug | Sildenafil Citrate | Young Adult | Epoprostenol - therapeutic use | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - therapeutic use | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Familial Primary Pulmonary Hypertension | Treatment Outcome | Piperazines - therapeutic use | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Epoprostenol - analogs & derivatives | Sulfonamides - therapeutic use | Exercise Tolerance - physiology | Adolescent | Aged | Epoprostenol - administration & dosage | Treprostinil | Dosage and administration | Research | Drug therapy | Patient outcomes | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink
by Matthews, Anthony and Langan, Sinéad M and Douglas, Ian J and Smeeth, Liam and Bhaskaran, Krishnan
PLoS Medicine, ISSN 1549-1277, 06/2016, Volume 13, Issue 6, pp. e1002037 - e1002037
Background Laboratory evidence suggests that reduced phosphodiesterase type 5 (PDE5) expression increases the invasiveness of melanoma cells; hence,... 
CPRD | POPULATION | MEDICINE, GENERAL & INTERNAL | BIAS | ERECTILE DYSFUNCTION | Melanoma - epidemiology | Young Adult | Melanoma - chemically induced | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Risk Factors | Adult | Male | Aged | United Kingdom - epidemiology | Cohort Studies | Usage | Oncology, Experimental | Melanoma | Colorectal cancer | Family medicine | Research | Health aspects | Epidemiology | Skin cancer | Cancer | Phosphodiesterases | Risk factors | Studies | Health risk assessment | Primary care | Socioeconomic factors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma
by Seftel, Allen D., MD
Journal of Urology, The, ISSN 0022-5347, 2016, Volume 195, Issue 3, pp. 713 - 715
Urology | Animals | Erectile Dysfunction - drug therapy | Melanoma - chemically induced | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Male | Skin Neoplasms - chemically induced | Impotence | Usage | Melanoma | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Adulteration of Purported Herbal and Natural Sexual Performance Enhancement Dietary Supplements with Synthetic Phosphodiesterase Type 5 Inhibitors
by Campbell, Neil and Clark, John P and Stecher, Vera J and Thomas, John W and Callanan, Amy C and Donnelly, Brian F and Goldstein, Irwin and Kaminetsky, Jed C
The Journal of Sexual Medicine, ISSN 1743-6095, 07/2013, Volume 10, Issue 7, pp. 1842 - 1849
Many products labeled “herbal” or “all natural” (herbal/natural) that claim to enhance sexual performance and imply use for the treatment of erectile... 
Erectile Dysfunction | Phosphodiesterase Type 5 Inhibitors | Sildenafil | Herbal Medicine | UROLOGY & NEPHROLOGY | TREATING ERECTILE DYSFUNCTION | Nonprescription Drugs - therapeutic use | Sulfones - therapeutic use | United States | Humans | Male | Piperazines - therapeutic use | Dietary Supplements - analysis | Sildenafil Citrate | Tadalafil | Drug Labeling | Piperazines - analysis | Erectile Dysfunction - drug therapy | Mass Spectrometry | Phosphodiesterase 5 Inhibitors - analysis | Chromatography, Liquid | Nonprescription Drugs - chemistry | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - analysis | Purines - therapeutic use | Carbolines - analysis | Sulfones - analysis | Carbolines - therapeutic use | Product counterfeiting | Impotence | Medicine, Botanic | Dietary supplements | Medicine, Herbal | Liquid chromatography | Drug approval | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma
by Penson, David F., MD, MPH
Journal of Urology, The, ISSN 0022-5347, 2015, Volume 194, Issue 6, pp. 1710 - 1711
Urology | Animals | Erectile Dysfunction - drug therapy | Melanoma - chemically induced | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Male | Skin Neoplasms - chemically induced | Impotence | Usage | Melanoma | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension
by Kramer, Tilmann and Dumitrescu, Daniel and Gerhardt, Felix and Orlova, Kristina and ten Freyhaus, Henrik and Hellmich, Martin and Baldus, Stephan and Rosenkranz, Stephan
International Journal of Cardiology, ISSN 0167-5273, 05/2019, Volume 283, pp. 152 - 158
Heart failure with preserved ejection fraction (HFpEF) is frequently associated with pulmonary hypertension (PH), which substantially impacts survival. Based... 
Pulmonary vascular resistance (PVR) | Diastolic pressure gradient (DPG) | Pulmonary artery compliance (PAC) | Phosphodiesterase type 5 inhibitor (PDE5i) | Pulmonary hypertension (PH) | Heart failure with preserved ejection fraction (HFpEF) | MORTALITY | DIAGNOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | PREDICTOR | EXERCISE CAPACITY | PROGNOSTIC VALUE | RIGHT-VENTRICULAR FUNCTION | ARTERIAL CAPACITANCE | PRESSURE-GRADIENT | CONTRACTILE FUNCTION | EPIDEMIOLOGY | Heart failure | Heart | Health aspects | Cardiac patients | Pulmonary hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text The Controversial Role of Phosphodiesterase Type 5 Inhibitors in the Treatment of Premature Ejaculation
by Jannini, Emmanuele A and McMahon, Chris and Chen, Juza and Aversa, Antonio and Perelman, Michael
The Journal of Sexual Medicine, ISSN 1743-6095, 08/2011, Volume 8, Issue 8, pp. 2135 - 2143
It is controversial whether or not the most frequent male sexual dysfunctions, premature ejaculation (PE) and erectile dysfunction (ED), share pathogenetic... 
SSRI | Tadalafil | Ejaculation | PDE5 Inhibitor | Sildenafil | Premature Ejaculation | Vardenfil | SEMINAL-VESICLE TISSUE | VAS-DEFERENS | INTERNATIONAL-SOCIETY | NITRIC-OXIDE SYNTHASE | SEXUAL HEALTH INVENTORY | MALE-RATS | TREATMENT PREFERENCE | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | CLINICAL-TRIAL METHODOLOGY | ERECTILE DYSFUNCTION | Ejaculation - physiology | Sexual Dysfunctions, Psychological - drug therapy | Sexual Dysfunction, Physiological - physiopathology | Erectile Dysfunction - drug therapy | Humans | Sexual Dysfunction, Physiological - drug therapy | Sexual Dysfunctions, Psychological - physiopathology | Male | Phosphodiesterase 5 Inhibitors - therapeutic use | Ejaculation - drug effects | Nitric Oxide - metabolism | Phosphodiesterase 5 Inhibitors - pharmacology | Premature ejaculation | Care and treatment | Impotence | Nitric oxide | Serotonin uptake inhibitors | Universities and colleges | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights